ナノマテリアルベースの精密医療による異所性がん治療の最近の進歩
Min Luo1, Fu-Kun Zhao1, Cang-Hong Ouyang1
1Department of Clinical Medicine, The Third Affiliated Hospital of Zunyi Medical University, The First People's Hospital of Zunyi, Zunyi, 563000, Guizhou, China.
Journal of nanobiotechnology
|January 24, 2026
まとめ
このレビューは、がんの効果的なナノメディシン開発において、皮下モデルよりも異所性がんモデルを支持するものです。異所性がんは、標的がん治療の設計とテストを改善する、ヒトのがんをより良く模倣します。
科学分野:
- 腫瘍学
- ナノメディシン
- トランスレーショナルリサーチ
背景:
- がんの世界的負担は、高度な治療戦略を必要とします。
- 皮下腫瘍モデルは、ヒトのがんの複雑さと転移を不十分にしか表していません。
- 臓器特異的な障壁と腫瘍微小環境(TME)は、治療効果にとって重要です。
研究 の 目的:
- 異所性がん-TMEを考慮したナノメディシン設計へのパラダイムシフトを提唱すること。
- 異所性がんモデルを使用して、12のがん腫におけるナノセラピューティクスの系統的評価を行うこと。
- 次世代の精密腫瘍学プラットフォームのロードマップを提供すること。
主な方法:
- 12のがん腫にわたる最近のナノセラピューティクスの進歩のレビュー。
- ナノセラピューティクスを、障壁貫通型、転移標的型、TME応答型のシステムに分類すること。
- 異所性がんモデルと皮下モデルを使用した研究からのデータの統合。
主要な成果:
- 異所性がんは、皮下モデルと比較して、ナノドラッグの浸透と有効性を評価するためのより厳密なプラットフォームを提供します。
- ナノセラピューティクスは、臓器特異的な障壁を克服し、転移を標的とするように設計されています。
- マイクロ環境応答性ナノメディシンは、局所的な腫瘍刺激に適応する上で有望です。
結論:
- ナノメディシンの臨床的成功には、異所性がんモデルへの移行が不可欠です。
- 製造、ナノと生体のインターフェース、安全性における課題に対処する必要があります。
- 将来の方向性には、患者由来異種異種移植片(PDOX)および精密腫瘍学のための適応型ナノシステムが含まれます。
関連する概念動画
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Uncertainty in Measurement: Accuracy and Precision
100.5K
Scientists typically make repeated measurements of a quantity to ensure the quality of their findings and to evaluate both the precision and the accuracy of their results. Measurements are said to be precise if they yield very similar results when repeated in the same manner. A measurement is considered accurate if it yields a result that is very close to the true or the accepted value. Precise values agree with each other; accurate values agree with a true value.
100.5K
Accuracy and Precision
14.8K
Scientists typically make repeated measurements of a quantity to ensure the quality of their findings and to evaluate both the precision and the accuracy of their results. Measurements are said to be precise if they yield very similar results when repeated in the same manner. A measurement is considered accurate if it yields a result that is very close to the true or the accepted value. Precise values agree with each other; accurate values agree with a true value. Highly accurate...
14.8K
Microorganisms in Medicine and Therapeutics
1.0K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.0K
Gene Therapy
27.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.4K
Extraction: Advanced Methods
1.1K
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
1.1K


